Benefits
Reduced hair fall in androgenetic alopecia (branded RCT)
Reduced hair fall in androgenetic alopecia: in a 16-week randomized, double-blind, placebo-controlled trial (n=80), oral VISPO 400 mg/day significantly reduced hair fall and improved hair growth and density versus placebo in men and women with androgenetic alopecia. A single manufacturer-sponsored trial, so results are promising rather than conclusive.
Supports normal DHT balance (5-alpha-reductase pathway)
Oral VISPO lowered serum dihydrotestosterone (DHT) versus baseline and placebo. The proposed mechanism is partial inhibition of 5-alpha-reductase, the enzyme that converts testosterone to DHT — the same pathway targeted by finasteride, but botanical and milder. DHT is central to both androgenetic hair thinning and prostate enlargement.
Prostate and lower urinary tract support
Saw palmetto's traditional use is benign prostatic hyperplasia (BPH) and lower-urinary-tract symptoms. A branded VISPO BPH trial reported improvements in urological and androgen-deficiency measures. Honest framing: across the wider saw palmetto literature the evidence is mixed — some trials positive, several large high-quality trials null.
Oral use is the relevant route on this site
The branded hair trial tested VISPO both as an oral softgel and as a 20 percent topical scalp formulation. This site covers oral supplements only, so the oral 400 mg/day arm is the relevant evidence here; the topical arm is a different route and is outside the site's scope.
Generally well tolerated
Saw palmetto has a long use history and a favorable tolerability profile; a meta-analysis indicates it does not impair male sexual function, in contrast to pharmaceutical 5-alpha-reductase inhibitors.
Mechanism of action
5-alpha-reductase inhibition
Saw palmetto fatty acids and sterols partially and non-competitively inhibit 5-alpha-reductase (types I and II), reducing conversion of testosterone to DHT. Lower local DHT eases androgen pressure on scalp hair follicles and prostate tissue.
Anti-androgenic and anti-inflammatory action at the follicle and prostate
Beyond 5-alpha-reductase, saw palmetto lipids may reduce DHT binding at androgen receptors and dampen local inflammatory signaling, both relevant to follicle miniaturization and prostatic hyperplasia.
Fatty-acid and phytosterol nourishment
The free fatty acids and β-sitosterol provide the lipophilic substrate behind saw palmetto's biological activity; CO₂ extraction yields a high-purity oil and the phytosterol-enriched grade concentrates the β-sitosterol fraction.
Clinical trials
Sudeep HV et al., Clinical, Cosmetic and Investigational Dermatology, 2023. Randomized, double-blind, placebo-controlled, 4-arm.
80 adults (18–50 y) with mild-to-moderate androgenetic alopecia
Subjects received oral 400 mg/day VISPO, a 20% topical VISPO, or matching placebos once daily for 16 weeks. This is an oral-only site, so the oral 400 mg/day arm is the relevant one and the 20% topical arm is a different route that is outside the site's scope. The oral arm reduced hair fall by about 29 percent from baseline and increased hair density by about 5 percent from baseline, and lowered serum DHT versus placebo. The anagen to telogen ratio did not change significantly. Manufacturer-sponsored: Vidya Herbs employees are among the authors.
Sudeep HV et al., BMC Urology, 2020. Randomized, double-blind, placebo-controlled comparative study.
Men ~40–65 y with BPH / androgen-deficiency symptoms
Oral phytosterol-enriched saw palmetto oil (VISPO, 500 mg/day) improved urological and hormonal outcomes versus conventional saw palmetto oil and placebo. Manufacturer-sponsored; supports the prostate/LUTS use but needs independent replication.
Independent systematic reviews of Serenoa repens (Schwartzmann 2026; Paulis 2021).
Pooled BPH and male sexual-function populations
Across the broader non-branded literature, saw palmetto's BPH benefit is mixed. A 2020 to 2025 systematic review (Schwartzmann 2026) reported urinary symptom improvements in several trials, more consistently for beta-sitosterol-enriched and hexanic extracts, but it did not cover the older large placebo-controlled trials (STEP 2006 and CAMUS 2011), which found no benefit over placebo. A separate meta-analysis (Paulis 2021) found saw palmetto does not impair male sexual function, useful safety context versus pharmaceutical 5-alpha-reductase inhibitors.